Evidence map›Paper›PMID 40475430›Full record

ArticlebioRxiv : the preprint server for biology2025

Hepatocyte-specific CLSTN3B ablation impairs lipid droplet maturation and alleviates diet-induced steatohepatitis in mice.

Chuanhai Zhang, Dengbao Yang, Hiroyuki Suzuki, Jingxuan Chen, Jingjing Wang, Mengchen Ye, Jin Zhou, Qiyu Zeng, Meijuan Bai, Mei-Jung Lin and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chuanhai ZhangDepartment of Physiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Dengbao YangDepartment of Physiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Hiroyuki SuzukiDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Jingxuan ChenLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center.
Jingjing WangChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, Children's Research Institute Mouse Genome Engineering Core, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Mengchen YeXaira Therapeutics, Brisbane, CA, 94005, USA.
Jin ZhouDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Qiyu ZengChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, Children's Research Institute Mouse Genome Engineering Core, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Meijuan BaiDepartment of Physiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Mei-Jung LinDepartment of Physiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Jeon LeeLyda Hill Department of Bioinformatics, University of Texas Southwestern Medical Center.
Hao ZhuChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, Children's Research Institute Mouse Genome Engineering Core, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0002-8417-9698
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Xing ZengDepartment of Physiology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Marcel Bernard Mettlen · 2010 to 2026
$53.7M
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesU01CA283935 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN, SINGAL, AMIT · 2023 to 2025
$3.9M
Trial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6M
Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Epigallocatechin gallate for prevention of lethal cirrhosis complicationsR01CA282178 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2023 to 2026
$1.8M
Mechanistic Connection between Interorganellar Communication and Obesity-associated DiseasesR01DK135556 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Xing Zeng · 2023 to 2026
$1.7M
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosisU01CA288375 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI CHUNG, RAYMOND T, DIEHL, ANNA MAE ELIZABETH · 2023 to 2025
$1.3M
TEM for UT Southwestern Electron Microscopy Core FacilityS10OD021685 · OD · UT SOUTHWESTERN MEDICAL CENTER · PI LUBY-PHELPS, KATHERINE J · 2017 to 2017
$398k
NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS R01 CA282178NCI NIH HHS U01 CA283935NCI NIH HHS U01 CA288375NIDDK NIH HHS R01 DK135556NIH HHS S10 OD021685
6 · The paper itself

Abstract

Excessive lipid accumulation in hepatocytes, a hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD), can lead to progressive liver damage. Understanding the molecular mechanisms governing lipid storage in hepatocytes is essential for identifying therapeutic targets to halt MASLD progression. Here, we show a pivotal role for the protein calsyntenin 3β (CLSTN3B) in promoting lipid droplet (LD) maturation and lipid storage in hepatocytes. Previously characterized as an endoplasmic reticulum (ER)-LD contact protein that facilitates LD maturation in adipocytes, we now show that CLSTN3B expression is strongly induced in mouse hepatocytes by peroxisome proliferator-activated receptor gamma (PPARγ) in response to dietary caloric excess. Hepatocyte-specific deletion of CLSTN3B in mice significantly increases energy expenditure, reduces metabolic efficiency, and protects against diet-induced hepatic steatosis and fibrosis. Mechanistically, CLSTN3B deficiency causes reduced LD phospholipid coverage and increased lipase recruitment. This results in enhanced fatty acid oxidation driven by a futile cycle of lipolysis and re-esterification. Notably, human clinical data reveal a positive correlation between hepatic CLSTN3B expression and MASLD severity and progression, emphasizing its relevance to human disease. Together, our findings establish CLSTN3B as a key regulator of hepatocyte lipid storage and metabolic efficiency and highlight its potential as a therapeutic target in MASLD.

Identifiers

PMID40475430
PMCPMC12139921

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.